Bacteriophage compositions for treating Clostridium perfringens infections
JP2024516120A5Pending Publication Date: 2025-04-14アパロン エルティーディー
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- JP2023562277
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-04-09
- Filing Date
- 2022-04-08
- Publication Date
- 2025-04-14
AI Technical Summary
Technical Problem
The widespread use of antibiotics in agriculture to treat and prevent Clostridium perfringens infections in animals leads to antibiotic resistance and disrupts the microbiome, necessitating alternative treatments.
Method used
Development of species-specific lytic bacteriophages and their cocktails that target Clostridium perfringens, capable of lysing bacterial strains and preventing infections without collateral damage to the microbiome.
Benefits of technology
The bacteriophages effectively treat and prevent Clostridium perfringens infections in animals, including poultry, by specifically targeting and lysing the bacteria, thereby reducing the need for antibiotics and minimizing microbiome disruption.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000000_0000_ABST
Abstract
The present invention relates to the field of phage therapy. More specifically, it relates to providing phages, phage-based compositions and methods for treating or preventing bacterial, particularly Clostridium perfringens, infections in animals, including humans, aquaculture animals and livestock animals. The present invention also relates to the use of said compositions as feed ingredients and biological decontamination agents in feed products and foods for human and animal consumption.
Need to check novelty before this filing date? Find Prior Art